CC
GILD icon

Casdin Capital’s Gilead Sciences GILD Stock Holding History

Casdin Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200,000
Closed -$13M – 39
2019
Q4 		$13M Buy
+200,000
New +$13M 1.2% 26
2018
Q4 		– Sell
-50,000
Closed -$3.86M – 34
2018
Q3 		$3.86M Buy
+50,000
New +$3.78M 0.47% 33
2017
Q3 		– Sell
-60,000
Closed -$4.25M – 28
2017
Q2 		$4.25M Buy
+60,000
New +$3.99M 1.57% 24

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Casdin Capital's GILD Position: Q2 2020 in Review

Casdin Capital sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 175,000 shares — an estimated $13.1M sold.

Casdin Capital first reported a position in GILD in Q4 2016 and held it in 5 quarters. The position peaked at $13.1M in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • Casdin Capital reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • Casdin Capital sold 175,000 Gilead Sciences shares in Q2 2020, an estimated $13.1M.
  • Casdin Capital first reported a position in Gilead Sciences in Q4 2016 and held it in 5 quarters.
  • Casdin Capital's Gilead Sciences position peaked at $13.1M in Q1 2020.
  • 1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Casdin Capital's 13F filing for Q2 2020, filed 14 Aug 2020.